EditorialA patient sample awaits processing during an antibody trial in Mesa, Ariz. for Regeneron and Eli Lilly on Wednesday, Aug. 12, 2020. (Adriana Zehbrauskas/The New York Times)
EditorialTest kits for new patients at a monoclonal antibody clinical trial site in Mesa, Ariz. for Regeneron and Eli Lilly on Wednesday, Aug. 12, 2020. (Adriana Zehbrauskas/The New York Times)